John Fesko serves as the President and Chief Business Officer at Natera, Inc., a leading company in the field of genetic testing and diagnostics. With a strong background in business development and strategic planning, Fesko has been instrumental in guiding Natera's growth and expansion. Prior to joining Natera, he held various leadership positions at notable healthcare and biotechnology firms, where he honed his skills in driving innovation and commercialization of cutting-edge technologies. At Natera, Fesko oversees the company's business development, marketing, and sales strategies, playing a key role in expanding the company's reach and impact in the genetic testing market. Under his leadership, Natera has successfully launched several groundbreaking products, including the Panorama non-invasive prenatal test and the Signatera molecular residual disease test. These innovations have not only improved patient outcomes but have also solidified Natera's position as a leader in the industry. Fesko's achievements at Natera extend beyond product development. He has been pivotal in forging strategic partnerships and collaborations that have enabled the company to broaden its service offerings and enter new markets. His vision and leadership have been crucial in navigating the complex landscape of genetic testing and diagnostics, ensuring that Natera remains at the forefront of the industry. As President and Chief Business Officer, Fesko continues to drive Natera's mission of transforming the way genetic information is used to improve human health.